General
Preferred name
GSK461364
Synonyms
GW843682X ()
KIN001-134 ()
GSK-461364 ()
GSK461364, GSK461364A ()
GSK461364A ()
GSK 461364 ()
GSK-461364A ()
Gsk 461364 ()
P&D ID
PD003618
CAS
929095-18-1
Tags
available
drug candidate
Drug indication
Solid tumour/cancer
non-Hodgkins lymphoma
Non-hodgkin lymphoma
Drug Status
investigational
Max Phase
1.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
GSK-461364A is an inhibitor of polo-like kinase 1 (PLK1) . It was tested in preclinical studies.
(GtoPdb)
DESCRIPTION
GSK461364 is a selective, reversible and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with a Ki value of 2.2 nM.
PRICE
131
DESCRIPTION
inhibitor of polo-like kinase 1 (PLK1)
(Informer Set)
DESCRIPTION
GSK461364 (GSK461364A)(Ki=2.2 nM) inhibits purified Plk1 .The specificity of GSK461364 for Plk1 is more than 1000-fold over Plk2/3.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
76
Organisms
0
Compound Sets
25
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Drugs
Chemical proteomics reveals the target landscape of 1,000 kinase inhibitors
Clinical kinase drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugMAP
EU-OPENSCREEN Bioactive Compound Library
EUbOPEN Chemogenomics Library
Guide to Pharmacology
Informer Set
Kinase Chemogenomic Set (KCGS)
Kinase Inhibitors (best-in-class)
LSP-MoA library (Laboratory of Systems Pharmacology)
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Welcome Trust Cancer Drugs
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
26
Molecular Weight
543.19
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
1
Rotatable Bonds
7
Ring Count
5
Aromatic Ring Count
4
cLogP
5.09
TPSA
76.62
Fraction CSP3
0.33
Chiral centers
1.0
Largest ring
6.0
QED
0.35
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
PLK1
PLK
PLK1, NEK2
Polo-like Kinase (PLK)
Compound status
clinical
Pathway
mitosis
Cell Cycle/DNA Damage
Cell Cycle/Checkpoint
Member status
member
MOA
PLK1 inhibitor
PLK inhibitor
Therapeutic Class
Anticancer Agents
Recommended Cell Concentration
100 nM
Source data
